Fairmount Funds Management as of June 30, 2022
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 27 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Biohaven Pharmaceutical Holding | 8.8 | $39M | 264k | 145.71 | |
| Axsome Therapeutics (AXSM) | 8.3 | $36M | 943k | 38.30 | |
| BioCryst Pharmaceuticals (BCRX) | 8.1 | $35M | 3.3M | 10.58 | |
| Global Blood Therapeutics In | 7.0 | $31M | 953k | 31.95 | |
| Argenx Se Sponsored Adr (ARGX) | 6.4 | $28M | 74k | 378.89 | |
| Neurocrine Biosciences (NBIX) | 6.3 | $28M | 283k | 97.48 | |
| Insmed Com Par $.01 (INSM) | 6.0 | $26M | 1.3M | 19.72 | |
| Cogent Biosciences (COGT) | 5.7 | $25M | 2.8M | 9.02 | |
| Nuvalent Inc-a (NUVL) | 5.3 | $23M | 1.7M | 13.56 | |
| Enanta Pharmaceuticals (ENTA) | 5.1 | $22M | 469k | 47.27 | |
| Beigene Sponsored Adr (BGNE) | 4.1 | $18M | 111k | 161.85 | |
| Cti Biopharma | 3.1 | $13M | 2.2M | 5.97 | |
| Point Biopharma Global | 2.9 | $13M | 1.8M | 6.81 | |
| Dbv Technologies Sa Sponsored Adr | 2.8 | $12M | 4.8M | 2.55 | |
| Miragen Therapeutics (VRDN) | 2.5 | $11M | 944k | 11.57 | |
| Annexon (ANNX) | 2.5 | $11M | 2.9M | 3.77 | |
| Olema Pharmaceuticals (OLMA) | 2.5 | $11M | 2.7M | 4.07 | |
| ACADIA Pharmaceuticals (ACAD) | 2.4 | $11M | 752k | 14.09 | |
| Tyra Biosciences (TYRA) | 2.3 | $10M | 1.4M | 7.15 | |
| Amarin Corp Spons Adr New (AMRN) | 1.9 | $8.3M | 5.6M | 1.49 | |
| Keros Therapeutics (KROS) | 1.7 | $7.5M | 273k | 27.63 | |
| Trevi Therapeutics (TRVI) | 1.0 | $4.6M | 1.6M | 2.81 | |
| Iovance Biotherapeutics (IOVA) | 1.0 | $4.3M | 390k | 11.04 | |
| Verona Pharma Sponsored Ads (VRNA) | 0.9 | $3.9M | 927k | 4.19 | |
| Instil Bio | 0.7 | $3.1M | 674k | 4.62 | |
| Astria Therapeutics (ATXS) | 0.6 | $2.7M | 912k | 3.00 | |
| Allakos (ALLK) | 0.1 | $461k | 147k | 3.13 |
